Background: Widespread metabolic disturbances are linked to chronic hepatitis virus infection. Steatosis is caused by HCV's interference with lipid metabolism. Low lipid profiles and the development of chronic liver disease are both associated with hepatitis C virus infection. Objective: We aimed to evaluate the effect of direct-acting antiviral therapy on serum lipid profile among Egyptians with chronic hepatitis C infection. Patients and Methods: Sixty individuals with chronic hepatitis C infection who were given direct-acting antiviral treatment were analyzed in this study. 30 naïve patients received (sofosbuvir + daclatasvir) during 12 weeks and 30 naïve Patients received (sofosbuvir + daclatasvir + ribavirin) during 12 weeks, lipid profile was done before and after treatment. Results: In our results, the lipid profile regarding triglyceride and cholesterol, before treatment and throughout the entire follow-up, neither group differed significantly from the other, but after three months, The levels of triglycerides and cholesterol were significantly high in both group with much more higher in group I. Regarding LDL and HDL no significant difference pretreatment was detected, but the increase in LDL and decrease in HDL were found in both groups and  in group I was significantly higher than group II after one and three months. Conclusion: we conclude that Direct acting antiviral drug treatment for chronic HCV infection resulted in a dramatic increase in lipid profile in these patients.